SUPPORT HOTLINE (888) 901-2226
Donate Now

Bladder Cancer News

HealthWell Foundation® now offers some financial assistance to Medicare patients with bladder cancer.

Bladder and Urothelial Cancers Fund Opens at HealthWell Foundation The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has opened a new fund to provide copayment and premium assistance to eligible Medicare patients living with bladder or urothelial cancer. Through the fund, HealthWell will

Read More

Bladder Cancer: A Patient-Friendly Guide to Understanding Your Diagnosis and Treatment Options is now available

Following a bladder cancer diagnosis in 2007, David Pulver went for a second opinion to Dr. Mark Schoenberg, a renowned urologist and expert in the field of urology. Together and alongside other doctors and patients, they wrote a patient-friendly book for those diagnosed with this disease. Bladder Cancer: A Patient-Friendly Guide to Understanding Your

Read More

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma

The FDA has now approved Merck’s KEYTRUDA® (pembrolizumab) as a first-line treatment for patients who are cisplatin-ineligible diagnosed with locally advanced or metastatic urothelial carcinoma. Additionally, second-line treatment in patients who are platinum-ineligible and have disease progression during or following chemotherapy or within 12 months of neoadjuvant or adjuvant treatment

Read More

Positive data from Phase 3 US Blue Light Cystoscopy with Cysview® study presented at AUA 2017 Meeting

On Sunday, May 14th, at the American Urological Association (AUA) 2017 Meeting in Boston, MA, Photocure ASA announced the latest data from their Phase 3 study with Blue Light Flexible Cystoscopy (BLFC™) with Hexvix®/Cysview®. This study showed that in 21.5% of the patients undergoing surveillance cystoscopy, a bladder cancer recurrence

Read More

New Guidelines for Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer!

For the first time for any type of malignancy, the American Urological Association (AUA), the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) have formulated an evidence-based guideline for the treatment of non-metastatic muscle-invasive bladder cancer. BCAN Co-Founder,

Read More